

Special Issue

Receptor-Binding Domain-Based Vaccines Against SARS-CoV-2

Message from the Guest Editor

The emergence of the COVID-19 pandemic in 2019 led to unprecedented efforts in vaccine development. Effective vaccines using various platforms have played a vital role in controlling the pandemic. Initially, most subunit vaccines targeted the spike protein of SARS-CoV-2. However, vaccines based on the spike protein's receptor-binding domain (RBD) have also proven themselves to be effective. The neutralizing antibodies target the RBD, which is smaller than the whole spike protein. This focus can enhance manufacturing and help minimize non-neutralizing antibody production. This Special Issue invites submissions of original research, reviews, clinical trial results, and opinions related to RBD and other spike protein subdomains.

Guest Editor

Dr. Puthupparampil Scaria

Conjugation Group at Laboratory of Malaria Immunology & Vaccinology (LMIV)/NIAID/NIH, Rockville, MD, USA

Deadline for manuscript submissions

28 February 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/230598

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).